RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma

BACKGROUND: Immunotherapeutic targets in multiple myeloma (MM) have variable expression height and are partly expressed in subfractions of patients only. With increasing numbers of available compounds, strategies for appropriate choice of targets (combinations) are warranted. Simultaneously, risk as...

Descripción completa

Detalles Bibliográficos
Autores principales: Emde-Rajaratnam, Martina, Beck, Susanne, Benes, Vladimir, Salwender, Hans, Bertsch, Uta, Scheid, Christoph, Hänel, Mathias, Weisel, Katja, Hielscher, Thomas, Raab, Marc S., Goldschmidt, Hartmut, Jauch, Anna, Maes, Ken, De Bruyne, Elke, Menu, Eline, De Veirman, Kim, Moreaux, Jérôme, Vanderkerken, Karin, Seckinger, Anja, Hose, Dirk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684778/
https://www.ncbi.nlm.nih.gov/pubmed/38035078
http://dx.doi.org/10.3389/fimmu.2023.1286700

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684778/
https://www.ncbi.nlm.nih.gov/pubmed/38035078
http://dx.doi.org/10.3389/fimmu.2023.1286700

Ejemplares similares